Translating Clinical Evidence into Practice: Improving Patient Outcomes with Triplet Therapy in mHSPC
Release Date: January 29, 2026
Expiration Date: July 28, 2026
Estimated time to complete activity: 0.75 credit (0.25 credit modules)
Jointly provided by Postgraduate Institute for Medicine and QDcme
As a learner about to begin this educational activity, here’s what you can expect—and why it matters for your practice.
Why This Matters
Triplet therapy with ADT, docetaxel, and an androgen receptor signaling inhibitor (ARSI) is now a standard of care for mHSPC. Identifying when and how to integrate triplet regimens into prostate cancer care can be challenging.
This activity was designed specifically for community oncologists and urologists who want to strengthen their understanding of factors influencing the selection of triplet versus doublet therapy, adverse event management, and cardiovascular care in mHSPC. The three modules include a review of clinical trial data, guideline and expert recommendations, case discussions, and strategies for assessment and management of cardiovascular risk.
- Through evidence-based discussions and real-world case scenarios, you’ll:
- Review current treatment algorithms and key data from clinical trials of triplet therapy
Translate the latest guideline recommendations into practical decisions for your patients. - Explore how to optimize therapy selection for high- and low-volume disease, manage toxicity, and coordinate with the multidisciplinary team.
- Learn strategies to mitigate cardiovascular risk and enhance patient safety through collaboration with cardio-oncology teams.
This course will equip you with clear, evidence-based insights to confidently implement treatment intensification and improve outcomes for your patients with mHSPC.
Faculty
Andrew J Armstrong
MD ScM FACP
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research, Duke Cancer Institute Center for Prostate and Urologic Cancers
Division of Medical Oncology
Departments of Medicine and Urology, Duke University, Durham, North Carolina
Alicia K. Morgans
MD, MPH, FASCO
Associate Professor
Harvard Medical School
Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Joshua D. Mitchell
MD, MSCI, FACC, FIC-OS
Associate Professor of Medicine
Director Cardio-Oncology Center of Excellence
Washington University
St. Louis, Missouri
Clinical Case Creation
Joseph Park
MD
Clinical Faculty
Department of Internal Medicine
Division of Medical Oncology
Duke Raleigh Cancer Center
Raleigh, North Carolina
Learning Objectives
- Identify key patient-specific factors, including disease volume, timing of metastasis, and fitness, that influence treatment decisions in mHSPC.
- Apply evidence-based strategies to manage adverse events and improve adherence to triplet therapy protocols.
- Implement standardized cardiovascular assessment protocols, including ECGs and biomarker evaluations, prior to initiating ADT or ARPI therapy.
- Apply evidence-based strategies for managing cardiovascular complications associated with ADT and ARPI in collaboration with multidisciplinary teams
How the Learning Works
You’ll be using the QDcme Practic-AI platform, which adapts to your needs:
- Flexible Modules: Short, 15-minute sessions fit your busy schedule and cover essential topics through a mix of video explainers, interactive cases, and evidence-based summaries.
- Real-World Scenarios: You’ll engage with practical, case-based exercises that mirror challenges you see in your own clinic—like explaining biomarker testing to patients or managing complex irAEs.
- On-Demand Support: An AI chatbot is available for quick clinical questions, summarizing medical literature, and reinforcing key concepts as you go using a verified accurate knowledgebase.
Support Statement
This activity was supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
Target Audience
This activity is designed to meet the professional educational needs of community-based medical oncologists, urologists, nurse practitioners and physician assistants who treat and or manage patients with genitourinary cancers.
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Andrew J Armstrong MD ScM FACP
Advisory Board: Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Exelixis, Novartis, Medscape, Telix, Duality Bio, MedIQ, IDEOlogy, Sumitomo, and Precede Bio
Research: Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Pathos, Amgen, Novartis, Fibrogen (to Duke)
Alicia K. Morgans, MD, MPH, FASCO
Advisory Board: Astellas, AstraZeneca, BMS, Bayer, Curium, Exact Sciences, Lantheus, Merck, Johnson & Johnson, Novartis, Pfizer, Telix, Tolmar
Joshua D. Mitchell, MD, MSCI, FACC, FIC-OS
Advisory Board: Alnylam, AstraZeneca, BridgeBio, Pfizer
Research: Abbott Laboratories, Myocardial Solutions
Joseph Park, MD
Advisory Board: MedScape, Ideology Health
Research: Tempus
The PIM planners and others have nothing to disclose. The QDcme planners and others have nothing to disclose
All relevant financial relationships have been mitigated.
Method of Participation and Request for Credit
- Select the first module to begin the activity, indicated by the “Module 1” button
- Complete the content within the module
- To evaluate and claim credit for a module after completing, indicate your desired form of credit and complete the evaluation.
- Provide your name and email to complete the evaluation.
- Your certificate will be generated with the information provided and sent to your email address.
- Repeat the previous steps for each module.
If you have questions regarding the certification of this activity, please contact QDcme via email at info@QDcme.com.
Joint Accreditation Statement
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and QDcme Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designations
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours
Hardware/Software Requirements (Required for Internet-based ACPE activities only)
Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.
Policy on Privacy and Confidentiality (Required for Internet-based ACPE activities only)
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Credit Designations
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.